论文部分内容阅读
目的探讨尿激酶联合阿托伐他汀钙片对ST段抬高型心肌梗死患者的治疗价值。方法选取2014年1月至2015年12月营口开发区中心医院收治86例的ST段抬高型心肌梗死患者作为研究对象,采用随机数字表法将其分为甲组和乙组,各43例。甲组患者采用尿激酶联合阿托伐他汀钙片进行治疗,乙组患者给予常规尿激酶溶栓治疗,比较两组患者临床效果、血脂水平及不良反应发生情况。结果甲组患者治疗的总有效率明显高于乙组,差异有统计学意义(P<0.05);治疗后,甲组患者的三酰甘油、总胆固醇及低密度脂蛋白胆固醇水平均明显低于乙组,高密度脂蛋白胆固醇水平明显高于乙组,差异均有统计学意义(均P<0.05);甲组患者的不良反应发生率明显低于乙组,差异有统计学意义(P<0.05)。结论尿激酶联合阿托伐他汀治疗ST段抬高型心肌梗死临床效果显著,能有效改善患者血脂水平,且不良反应发生率较低。
Objective To investigate the therapeutic value of urokinase combined with atorvastatin calcium in patients with ST-segment elevation myocardial infarction. Methods From January 2014 to December 2015, 86 patients with ST-elevation myocardial infarction admitted to Central Hospital of Yingkou Development Zone were enrolled in this study. Patients were divided into group A and group B by random number table, and 43 . Patients in group A were treated with urokinase and atorvastatin calcium tablets. Patients in group B were given routine urokinase thrombolysis. The clinical effects, blood lipid levels and adverse reactions in both groups were compared. Results The total effective rate of treatment in group A was significantly higher than that in group B (P <0.05). After treatment, the levels of triglyceride, total cholesterol and low density lipoprotein cholesterol in group A were significantly lower than those in group B Group B, high-density lipoprotein cholesterol levels were significantly higher than those in group B, the differences were statistically significant (all P <0.05); group A patients with adverse reactions was significantly lower than in group B, the difference was statistically significant (P < 0.05). Conclusion The combination of urokinase and atorvastatin has significant clinical effect on ST-segment elevation myocardial infarction, which can effectively improve the blood lipid level of patients with a lower incidence of adverse reactions.